

Appendix 5 (as supplied by the authors): Baseline characteristics (PS weighted) of inflammatory bowel disease patients initiating TNF- α inhibitors or non-biologic agents*

	Medicaid		Medicare		Optum Clinformatics	
	PS-weighted		PS-weighted		PS-weighted	
	TNF- α inhibitor initiators	Non-biologic initiators	TNF- α inhibitor initiators	Non-biologic initiators	TNF- α inhibitor initiators	Non-biologic initiators
	n=1429	n=4984	n=1472	n=5130	n=2252	n=6286
Demographic variables						
Age, years	32.3 ± 11.1	32.4 ± 11.0	53.4 ± 16.8	53.5 ± 16.7	37.0 \pm 12.6	37.1 ± 13.0
White race	73.62	74.02	85.12	85.21	-	-
Black race	17.49	17.14	10.67	10.77	-	-
Females	69.14	68.51	62.84	62.97	53.37	53.74
Type of IBD						
Crohn's disease	87.54	87.91	77.24	77.89	76.2	76.57
Ulcerative colitis	12.46	12.09	22.76	22.11	23.8	23.43
Other IBD-related medication use in last 6 months						
Cumulative days of 5-ASA compound use	32.2 ± 50.2	32.1 ± 48.5	45.4 ± 66.6	46.0 ± 68.3	46.3 ± 67.4	46.4 ± 64.3
Cumulative oral steroids (prednisone equivalent mgs)	773.5 ± 1390.9	748.1 ± 1514.0	794.7 ± 1223.0	790.8 ± 2992.0	870.1 ± 1231.9	869.3 ± 1206.9
IBD-related healthcare utilization in last 6 months						
Mean number of hospitalizations with IBD	0.3 \pm 0.6	0.3 \pm 0.6	0.3 \pm 0.6	0.3 \pm 0.7	0.3 \pm 0.6	0.3 \pm 0.6
Mean number of gastroenterologist visits	-	-	-	-	5.5 \pm 6.0	5.5 \pm 6.6
Variables indicating IBD severity						
Anemia	22.04	22.12	35.6	36.19	23.18	22.54
Blood transfusion	3.29	3.14	5.91	6.1	2.62	2.58
Clostridium difficile infection	1.19	1.31	2.51	2.48	2.09	2.21
Active fistulizing or internal penetrating disease	7.14	6.96	7.68	7.25	7.1	7.08
Malnutrition	3.5	3.44	6.39	6.7	3.29	3.5
Obstructing or stricturing disease	11.83	11.99	14.95	14.84	12.03	11.86
Total parenteral nutrition	2.45	2.49	2.24	2.19	2.09	2.19
Volume depletion	17.91	18.17	25.61	25.82	15.32	15.27
Intra-abdominal surgical procedures	19.94	20.09	19.63	19.95	30.06	30.27
Other risk factors for VTE						
Extremity fractures	1.61	1.57	2.51	2.55	0.89	0.98
Pregnancy	7.42	6.88	1.22	1.27	2.26	1.93
Cardiovascular surgical procedures	6.16	6.49	7.34	7.22	4.62	4.59
Obstetric surgical procedures	1.82	1.71	0.95	0.93	0.67	0.5
Musculoskeletal surgical procedures	1.47	1.28	0.88	0.85	0.62	0.66

Appendix to: Desai RJ, Gagne JJ, Lii J, et al. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor- α inhibitors or nonbiologic agents: a cohort study. *CMAJ* 2017. DOI:10.1503/cmaj.161485.

Copyright © 2020 The Author(s) or their employer(s).

To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Non-oral contraceptives	2.73	2.77	0	0	1.87	1.87
Oral contraceptives	9.52	9.55	2.72	2.65	11.15	11.45
Hormone replacement therapy	2.52	2.61	5.03	4.96	2.13	2.15
Comorbidities, comedications, and healthcare use factors						
Myocardial infarction	0.56	0.51	1.56	1.52	0.44	0.45
Angina	1.75	1.77	4.48	4.56	1.11	1.05
COPD	16.79	16.93	28.87	28.7	12.97	12.78
Cerebrovascular events	1.47	1.48	4.89	4.81	0.84	0.83
Heart failure	1.75	1.87	5.57	5.74	0.62	0.73
Diabetes	6.09	6.37	21.88	21.79	5.6	5.57
Hyperlipidemia	7.21	7.41	44.43	44.37	16.56	16.4
Hypertension	15.61	15.63	50.68	51.29	17.01	16.63
Obesity	6.09	6.15	12.16	12.19	4.57	4.49
Rheumatoid arthritis	5.39	5.64	17.66	18.13	7.15	7.48
Smoking	20.99	21.06	27.51	27.26	11.15	11.04
Antiplatelet agents	0.35	0.42	3.19	3.16	0.49	0.58
Aspirin	0.63	0.62	0	0	0.4	0.3
Cox-II inhibitors	3.01	3.17	3.46	3.35	1.82	1.65
Non-selective NSAIDs	14.28	14.68	17.6	17.81	10.21	10.13
Opioids	54.44	53.83	57.54	57.17	43.25	42.26
Statins	2.45	2.63	19.29	18.9	4.44	4.48
Number of office visits	4.9±4.1	4.9±4.1	7.1±5.1	7.1±5.5	5.4±3.9	5.4±3.9
Number of emergency department visits	1.3±2.1	1.3±2.0	1.2±2.4	1.2±2.6	0.6±1.3	0.6±1.1
Number of distinct drugs used	7.6±6.1	7.7±6.1	10.1±6.2	10.1±6.3	6.7±4.9	6.7±4.8

Note: TNF = tumour necrosis factor.

*Sample sizes for the weighted population in this table are smaller than sample sizes in the unweighted population (see Table 1 of the main article) because of exclusion of noncomparable patients through propensity score trimming.